Phase III study of ribociclib (LEE011) in combination with fulvestrant for the treatment of postmenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (aBC) who have received no or only one line of pri

Affiliation auteurs!!!! Error affiliation !!!!
TitrePhase III study of ribociclib (LEE011) in combination with fulvestrant for the treatment of postmenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (aBC) who have received no or only one line of pri
Type de publicationJournal Article
Year of Publication2016
AuteursFasching P.A, Jerusalem G., Pivot X., Martin M., De Laurentiis M., Blackwell K., Esteva F.J, Paquet-Luzy T., Tang Z., Lorenc K.R, Slamon D.J
JournalCANCER RESEARCH
Volume76
Date PublishedFEB 15
Type of ArticleMeeting Abstract
ISSN0008-5472
DOI10.1158/1538-7445.SABCS15-OT2-01-02